News and Trends 8 Mar 2017 German Biotech closes Largest Series A Fundraising of 2017 So Far Breath Therapeutics has raised €43.5M that will be used to finalize development and launch a therapy to improve survival in lung transplant patients. Sofinnova Partners, one of the top biotech VCs in Europe, and the Belgian Gimv have co-led the Series A round of Breath Therapeutics, a German company focusing on treating pulmonary orphan indications. […] March 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 8 Mar 2017 International Women’s Day: An Infographic on Gender Diversity in Biotech Today we celebrate women and promote a more gender-inclusive industry. Biotech is infamous for its divide, but what are the numbers? Whether it’s launching the next generation of insulin or running the business arm of one of Europe’s leading immuno-oncology biotechs, women have made major strides in biotechnology as some prominent leaders on the scene. “I […] March 8, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 7 Mar 2017 UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo transfer (ET). UPDATE (26/01/2017): ObsEva has disclosed plans to release 6.45M shares at $15 (€14) each, for a total of €90.3M. This large total reflects […] March 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Mar 2017 A New Transatlantic Partnership takes on Antibiotic Resistance The Swiss biotech BioVersys and the US company Aptuit have entered a new collaboration to target antibiotic resistances. BioVersys, based in Basel, is developing small molecules that interfere with bacterial resistance mechanisms. Its current research is focused on nosocomial infections (hospital infections) and tuberculosis. To advance the development of compounds against novel targets identified by BioVersys, the company has […] March 7, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 6 Mar 2017 The ‘Underdog of the UK?’ 8 Companies Proving the Welsh Biotech Scene How is biotech in Wales? We take a look at some companies based in the ‘Land of Song,’ their plans and their achievements. After taking a look at the vibrant biotech clusters in the UK like London and Cambridge and picking the top biotechs in Scotland, it’s time to direct our attention to the western part […] March 6, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 6 Mar 2017 How did this Biotech seal a €1B Deal with AstraZeneca? The CEO Explains We talked to the CEO of Bicycle Therapeutics, Kevin Lee, about how his company’s technology could cure not just cancer but also a raft of other diseases. Bicycle Therapeutics made a splashy debut in 2014 with a €25M fundraising round, only to outdo it with a €1B deal with AstraZeneca last fall. What’s the fuss? […] March 6, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Mar 2017 Meet the Finnish Bioartist using Yeast to Create Vanishing Photographs Johanna Rotko creates living art with yeast to explore the perishableness of matter and how we interact with nature around us. Johanna Rotko is a visual artist and photographer based in Kotka, Finland, that decided to explore alternative photographic methods. The result were yeastograms, living images made with yeast on petri dishes that disappear over […] March 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2017 An HIV Vaccine Eliminates the Virus in a Patient for 7 Months An HIV vaccine developed at the University of Oxford has kept 5 out of 15 patients completely free of HIV. One of the patients has already been clear for 7 months. AIDS affects over 36.7 million people. Antiretroviral therapy (ART) is the most common treatment, which kills those cells in which the virus is active. However, HIV can remain inactive and […] March 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 3 Mar 2017 Plants go Electronic with new Swedish Magic Sauce e-Plants can become a reality with a new technique that creates in vivo electronic circuits. But what are these bioelectronic plants for? A research team from the Linköping University has developed a ‘magic sauce’ that can transform the normal vascular system, through which they transport water and nutrients from the roots, into an electronic circuit. […] March 3, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 2 Mar 2017 There’s a New Record in Biotech Fundraising: Should We Believe the Hype? Illumina’s cancer diagnostics baby, GRAIL, has raked in a jaw-dropping $1B in Series B. Should Europe get on America’s level? A new genome sequencing company spun out of Illumina, GRAIL, has raised over $900M in a Series B fundraising round. That’s far and away the largest round ever; further, that’s more than most companies hope to be worth, […] March 2, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 1 Mar 2017 German Spin-off Scores Funding to Treat Atrial Fibrillation The Berlin-based startup OMEICOS Therapeutics announced the first closing of a series B financing round of €8.3M and the initiation of a Phase 1 clinical trial for the treatment of atrial fibrillation. OMEICOS Therapeutics, a spin-off from the Max Delbrueck Center for Molecular Medicine in Berlin, is taking the next step with its lead compound OMT-28 for […] March 1, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2017 Swedish Oncology Biotech makes a Large IPO for its Peptides The Swedish company Oncopeptides raised €68M with its IPO on Nasdaq Stockholm, which will allow the company to push their compound into phase III trials. Oncopeptides was founded in 2000 and is focused on the development of its lead compound Ygalo. After the company started a Phase II trial in patients with late stage relapsed and refractory multiple […] March 1, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email